These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Beta-blockers in hypertension.
    Author: Hansson L.
    Journal: J Hypertens Suppl; 1987 Aug; 5(3):S61-7. PubMed ID: 2889813.
    Abstract:
    Following the early and important observations more than two decades ago, by Prichard and Gillam that beta-blockers had a useful antihypertensive effect, this class of compounds has become widely accepted in the treatment of elevated arterial pressure. Today there are numerous different compounds available within the beta-blocker class, with marked differences in their ancillary properties. Undoubtedly, the blockade of beta 1-adrenoceptors is the effect needed to achieve the reduction in blood pressure, and this selectivity also offers some advantages from a safety point of view. However, in some circumstances, ancillary properties such as beta 2-blockade may offer advantages, as can intrinsic sympathomimetic activity. The fact that beta-blockers have become first-line treatment for hypertension in many countries and that memoranda produced by the World Health Organization and the International Society of Hypertension jointly advocate beta-blockers as one alternative for basic therapy reflects the positive balance between efficacy and side effects seen with these agents. It is also an indication that positive long-term clinical experience has been accumulated with beta-blockers. Finally, secondary prevention against coronary heart disease is well documented for beta-blockers. For this reason there have been great hopes for many years that beta-blockers would also have a primary preventive effect against coronary heart disease when used in the treatment of hypertension. Indications are now accumulating that, at least in some subgroups of patients, beta-blockers may have such an effect. Thus, although newer classes of compounds appear to be extremely competitive, beta-blockers are likely to play an important role in the treatment of hypertension for many years to come.
    [Abstract] [Full Text] [Related] [New Search]